Abstract
Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63.
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
Erratum For:
Low doses of CPS49 and flavopiridol combination as potential treatment for advanced
prostate cancer
Current Pharmaceutical Biotechnology
Title:Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Volume: 20 Issue: 12
Author(s): Florencia Zalazar, Paola De Luca, Kevin Gardner, William D. Figg, Roberto Meiss, Raúl G. Spallanzani, Pablo Vallecorsa, Belén Elguero, Javier Cotignola, Elba Vazquez and Adriana De Siervi*
Affiliation:
- Laboratorio de Oncologia Molecular y Nuevos Blancos Terapeuticos, Instituto de Biologia y Medicina Experimental (IBYME-CONICET), Buenos Aires,Argentina
Abstract:
Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63.
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
Export Options
About this article
Cite this article as:
Zalazar Florencia , Luca De Paola , Gardner Kevin , Figg D. William, Meiss Roberto , Spallanzani G. Raúl , Vallecorsa Pablo , Elguero Belén , Cotignola Javier , Vazquez Elba and Siervi De Adriana*, Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer, Current Pharmaceutical Biotechnology 2019; 20 (12) . https://dx.doi.org/10.2174/138920102012190919103433
DOI https://dx.doi.org/10.2174/138920102012190919103433 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Reactive Oxygen Species in Tumor Treatment and its Impact on Bone Marrow Hematopoiesis
Current Drug Targets CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Is Red Meat Required for the Prevention of Iron Deficiency Among Children and Adolescents?
Current Pediatric Reviews Possibilities and Limits of Ovarian Reserve Testing in ART
Current Pharmaceutical Biotechnology The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Backbone-Cyclized Peptides: A Critical Review
Current Topics in Medicinal Chemistry G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design The ACE Insertion/Deletion Polymorphism and Risk of Cancer, a Review and Meta-Analysis of the Literature
Current Cancer Drug Targets Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening